article

1. Lung cancer screening use among screening-eligible adults with disabilities..  Journal of the American Geriatrics Society.  72:1155-1165. 2024
2. "Celebrating Resilience": A review of abstracts on functional resilience at the International Society of Geriatric Oncology 2022 annual meeting..  Journal of geriatric oncology.  14:-. 2023
3. Barriers to and recommendations for integrating the age-friendly 4-Ms framework into electronic health records..  Journal of the American Geriatrics Society.  71:1573-1579. 2022
4. End-of-life care trajectories among older adults with lung cancer..  Journal of geriatric oncology.  14:-. 2022
5. Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study..  Journal of geriatric oncology.  14:-. 2022
6. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer..  Expert review of anticancer therapy.  22:861-874. 2022
7. Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer..  JAMA network open.  5:-. 2022
8. Characterization of older adults with cancer seeking acute emergency department care: A prospective observational study..  Journal of geriatric oncology.  13:943-951. 2022
9. Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer..  Health psychology : official journal of the Division of Health Psychology, American Psychological Association.  41:379-388. 2022
10. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis..  JTO clinical and research reports.  3:-. 2022
11. Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer..  JTO clinical and research reports.  3:-. 2022
12. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors..  Frontiers in immunology.  -. 2022
13. A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial..  Frontiers in oncology.  -. 2022
14. Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer..  Journal of palliative medicine.  25:932-939. 2022
15. Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy..  Frontiers in oncology.  -. 2022
16. Polypharmacy in older adults with cancer undergoing radiotherapy: A review..  Journal of geriatric oncology.  13:778-783. 2022
17. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry..  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.  17:661-674. 2022
18. Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non-Small Cell Lung Cancer Versus Community Controls..  Journal of the National Comprehensive Cancer Network : JNCCN.  20:118-125. 2022
19. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer..  Clinical lung cancer.  23:236-243. 2022
20. Psychological Symptom Trajectories and Non-Small Cell Lung Cancer Survival: A Joint Model Analysis..  Psychosomatic medicine.  84:215-223. 2022
21. Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies..  Frontiers in oncology.  -. 2021
22. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study..  JAMA oncology.  7:1856-1861. 2021
23. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers..  JAMA network open.  4:-. 2021
24. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival..  Cancer immunology, immunotherapy : CII.  71:1157-1165. 2021
25. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study..  Journal of the American Geriatrics Society.  70:136-149. 2021
26. Feasibility of implementing an exercise intervention in older adults with hematologic malignancy..  Journal of geriatric oncology.  13:234-240. 2021
27. Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice..  Journal of the National Comprehensive Cancer Network : JNCCN.  2021
28. Immunotherapy in Older Adults With Cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  39:2115-2127. 2021
29. Substance Abuse Risk and Medication Monitoring in Patients with Advanced Lung Cancer Receiving Palliative Care..  Journal of pain & palliative care pharmacotherapy.  35:91-99. 2021
30. Too Many Appointments: Assessing Provider and Nursing Perception of Barriers to Referral for Outpatient Palliative Care..  Palliative medicine reports.  2:137-145. 2021
31. Functional Disability Among Older Versus Younger Adults With Advanced Non-Small-Cell Lung Cancer..  JCO oncology practice.  17:e848-e858. 2021
32. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:915-921. 2021
33. Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:1055-1062. 2021
34. Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  1-10. 2021
35. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment..  Current medical research and opinion.  37:643-653. 2021
36. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events..  Cancer immunology, immunotherapy : CII.  70:2761-2769. 2021
37. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer..  Journal of geriatric oncology.  12:813-819. 2021
38. The aging microbiome and response to immunotherapy: Considerations for the treatment of older adults with cancer..  Journal of geriatric oncology.  12:985-989. 2021
39. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  29:3921-3932. 2021
40. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer..  Cancer immunology, immunotherapy : CII.  69:2403-2408. 2020
41. Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting..  Journal of geriatric oncology.  11:1324-1328. 2020
42. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life..  JCO oncology practice.  16:e1355-e1370. 2020
43. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions..  Journal of palliative medicine.  24:195-204. 2020
44. Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice..  BMC geriatrics.  20:-. 2020
45. Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects..  Patient preference and adherence.  927-937. 2020
46. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer..  JAMA network open.  3:-. 2020
47. Multidisciplinary telemedicine and the importance of being seen..  Journal of geriatric oncology.  11:1349-1351. 2020
48. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications..  BMC cancer.  20:-. 2020
49. Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer..  Journal of geriatric oncology.  11:960-968. 2020
50. Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration..  Journal of palliative medicine.  23:1038-1044. 2020
51. Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer..  Journal of pain and symptom management.  59:767-777.e1. 2019
52. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms..  Lung cancer (Amsterdam, Netherlands).  195-204. 2019
53. Patterns of pain medication use associated with reported pain interference in older adults with and without cancer..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  28:3061-3072. 2019
54. A story of connection: A tribute to Arti Hurria, MD..  Journal of geriatric oncology.  11:164-165. 2019
55. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers..  Journal of cancer research and clinical oncology.  145:2541-2546. 2019
56. Geriatric oncology research at the 2019 American Geriatrics Society (AGS) annual meeting: Joint perspectives from the Young International Society of Geriatric Oncology (SIOG) and AGS Cancer and Aging Special Interest Group..  Journal of geriatric oncology.  10:994-997. 2019
57. Treatment-Related Complications of Systemic Therapy and Radiotherapy..  JAMA oncology.  5:1028-1035. 2019
58. Mentoring pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD..  Journal of geriatric oncology.  11:335-337. 2019
59. Value-Added Decisions in Oncology..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  122-131. 2019
60. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer..  Journal of geriatric oncology.  10:669-672. 2019
61. Prioritization of Patient-Reported Outcomes by Women With Metastatic Breast Cancer..  JCO clinical cancer informatics.  1-3. 2019
62. Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment..  Annals of emergency medicine.  73:88-90. 2018
63. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials..  JAMA oncology.  4:-. 2018
64. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting..  JAMA.  320:469-477. 2018
65. Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults..  Journal of geriatric oncology.  10:60-67. 2018
66. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults..  Current oncology reports.  19:-. 2017
67. Information Needs of Older Women With Early-Stage Breast Cancer When Making Radiation Therapy Decisions..  International journal of radiation oncology, biology, physics.  98:733-740. 2017
68. Caring for the Older Population With Advanced Lung Cancer..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  587-596. 2017
69. Treatment Burden of Medicare Beneficiaries With Stage I Non-Small-Cell Lung Cancer..  Journal of oncology practice.  13:e98-e107. 2016
70. Gaps in nutritional research among older adults with cancer..  Journal of geriatric oncology.  7:281-92. 2016
71. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting..  Journal of geriatric oncology.  7:293-304. 2016
72. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  34:1438-42. 2016
73. The Treatment of Advanced Lung Cancer in the Elderly: The Role of a Comprehensive Geriatric Assessment and Doublet Chemotherapy..  Cancer journal (Sudbury, Mass.).  21:392-7. 2015
74. Reply to L.W. Cuttino et al..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  31:2227-9. 2013
75. A new approach to understanding racial disparities in prostate cancer treatment..  Journal of geriatric oncology.  4:1-8. 2013
76. Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  30:4302-7. 2012
77. The relationship between clinical benefit and receipt of curative therapy for prostate cancer..  Archives of internal medicine.  172:362-3. 2012